April 25th 2024
Despite the disproportionate effects of SARS-CoV-2 infection and severe outcomes on nursing home residents, less than 50% have received the updated 2023/2024 vaccine.
FDA Committee Endorses Full Approval of Paxlovid for COVID-19 Treatment
March 16th 2023The FDA's Antimicrobial Drugs Advisory Committee recommended approving Pfizer’s New Drug Application for Paxlovid to treat mild-to-moderate COVID-19 in adults at high risk of severe or fatal disease progression.
Read More
FDA Advisory Committee Recommends Approving First-Ever RSV Vaccine
February 28th 2023Pfizer indicates their RSV vaccine candidate, Abrysvo (RSVpreF), to prevent acute respiratory disease and lower respiratory tract disease caused by respiratory syncytial virus (RSV) in adults 60 years and older by active immunization.
Read More
If The PREP Act Sunsets, it Will Affect Pharmacists' Role With Vaccines, Access to Care
February 24th 2023A new report shows these providers are playing a larger role in vaccine administration, but without federal legislation codifying PREP, half the US states could determine not to continue this path for pharmacists and take away this now vital responsibility.
Read More
As US COVID-19 Vaccine Policy Pivots, CDC Publishes Prevention Measures for Immunocompromised
January 29th 2023In the latest Morbidity and Mortality Weekly Report, authors offer some strategies to avoid SARS-CoV-2 infection in this patient population as well as the US government changes course on COVID-19 vaccine policy.
Read More